Development of a microplate assay for serum chromogranin a (CgA): Establishment of normal reference values and detection of elevated CgA in malignant diseases

Journal of Clinical Laboratory Analysis

Volumn 13, Issue 6, 1999, Pages 312-319

  Wu, Tsu Lan ^a   Chang, Christine P Y ^a   Tsao, Kuo Chien ^a   Chien Feng, Sun ^a   Wu, James T ^b,c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c ARUP LABORATORIES   (United States)

Author keywords

Chromogranin A; Malignant diseases; Neuroendocrine cells; Neuroendocrine differentiation; Reference value

Indexed keywords

CHROMOGRANIN A;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CELL DIFFERENTIATION; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MALE; MALE GENITAL TRACT CANCER; NEUROSECRETORY CELL; PROSTATE CANCER; REFERENCE VALUE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHROMOGRANIN A; CHROMOGRANINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NEOPLASMS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SEX FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032743725     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2825(1999)13:6<312::AID-JCLA11>3.0.CO;2-1     Document Type: Article

References (22)

1. Deftos LJ. Chromogranin A. Its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 1991; 12:181-186.
2. Iacangelo AL, Eiden LE. Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept 1995;58:65-88.
3. O'Connor DT, Deftos LJ. Secretion of Chromogranin A by peptide-producing endocrine neoplasm. N Engl J Med 1986;314:1145-1151.
4. Boomsma F, Bhaggoe UM, Man In't Veld AJ, Schalekamp MA. Sensitivity and specificity of a new ELISA method for determination of Chromogranin A in the diagnosis of pheochromocytoma and neuroblastoma. Clin Chim Acta 1995;239:57-63.
5. Di SantíAgnese P, Cockett ATK. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996;78:357-361.
6. Di SantíAgnese P. Neuroendocrine differentiation in prostatic carcinoma. Cancer 1995;75:1850-1859.
7. Cussenot O, Villette JM. Valeri A, et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996;155:1340-1343.
8. Van de Voorde WM, Van Poppel HP, Verbeden EK, Oyen RH, Baert OV, Lauweryns JM. Morphologic and neuroendocrine features of adenocarcinoma arising in the transition zone and in the peripheral zone of the prostate. Modern Path 1995;8:591-598.
9. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson Jr. HF, Cathepsin D. Chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 1997;80:2109-2119.
10. Bemer A, Nesland J, Waehre H, Glide J. Fossa S. Hormone resistant prostatic adenocarcinoma: an elevation of prognostic factors in pre-and post-treatment specimens. Br J Cancer 1993;68:380-384.
11. Wu JT, Astill ME, Liu GH, Stephenson RA. Serum chromograniri A: early detection of hormonal resistance in prostate cancer patients. J Clin Lab Anal 1998;12:205.
12. Bajetta E, et al. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 1998;15:372-378.
13. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjolnerod OK, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997;30:1-6.
14. Wu JT, Zhang P, Astill ME, Lyons BW, Wu LH. Identification and characterization of c-erbB-2 proteins in serum, breast tumor tissue, and SK-BR-3 cell line. J Clin Lab Anal 1995;9:141-150.
15. Kadmon D, Thompson TC, Lynch GR. Elevated plasma chromogranin A concentrations in prostatic carcinoma. J Urol 1991;146:358-361.
16. Bosman FT. Neuroendocrine cells in non-endocrine tumors: what does it mean ? Verh Dtsch Ges Path 1997;81:62-72.
17. Crawford GA, Gyory AZ, Dallery DM, Kelly D. HPLC of urinary catecholamines in the presence of labetalol, captopril, and α-methyldopa. Clin Chem 1990;36:1849-1853.
18. Wu JT. Measurement of AFP and its lectin reactive isoforms in liver diseases and various malignancies. Annals of Clin Lab Sci 1990; 20:98-105.
19. Brown JA, Roberts CS. Elevated serum alpha-fetoprotein levels in primary gullbladder carcinoma without hepatic involvement. Cancer 1992;70:1838-1843.
20. Hoosein-NM; Logothetis-CJ; Chung-LW. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 1993;149:1209-1213.
21. Mezger MS, O'Connor DT. Plasma chromogranin A in renal failure: elevation proportional to degree of renal failure, and retention of immunoreactive fragments (abstract). Kidney Int 1986;29:198.
22. O'Connor DT, Randian MR, Carlton E, Cervenka JH, Hsiao RJ. Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem 1989;35:1631-1637.